Therefore, a cellular platform lacking secondary genomic alterations but retaining a strong functional link between p53 mutation and gliomagenesis is required to investigate the oncogenic role of mutant p53 in glioma initiation. The gene discussed is TP53; the disease is central nervous system cancer.